Is that why TCR2 Therapeutics Inc. (Nasdaq: TCRR) shares soared in the late hours on Friday?


    TCR2 Therapeutics Inc. (Nasdaq: TCRR), the stock surged higher in the after-market session as it was up 33.36% to $43.6. As a clinical-stage immunotherapy company with a pipeline of novel T cell-based therapies for cancer patients, we revealed today positive interim results from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial.

    In the first eight patients treated on the study, three PRs have been achieved based on RECIST 1.1 criteria by the November 24, 2020 data cutoff, with our very first patient had achieved a confirmed PR up to month six.

    Do You Own These 7 Inflation-Survival Stocks?

    Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

    Click here to get your free copy of the report


    Furthermore, the first patient-administered at a higher dose of gave-cel (1×108/m2) without lymphodepletion had a stable condition within two months without any noticeable toxicity, enabling patients to resume therapy with the addition of lymphodepletion at that dose.

    The toxicology profile remains manageable, with only two patients reporting gavo-cel-related non-hematological grade >2 toxicity to date and no indication of neurotoxicity or on-target, off-tumor side effects. In all patients, translational data demonstrated the expansion of TRuC-T cells and the induction of cytokines.


    Please enter your comment!
    Please enter your name here